YRYiming Ren

Yiming Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yiming Ren has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Li Teng

    Department of Craniomaxillofacial Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • Liya Yang

    Comprehensive Plastic Surgery Department Plastic Surgery Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100144 China

    1 shared publication
  • Quanyi Guo

    Institute of Orthopedics, The First Medical Center, Chinese PLA General Hospital, Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma and War Injuries PLA, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China

    1 shared publication
  • Shuyun Liu

    Department of Orthopedics, The First Medical Center, Chinese PLA General Hospital, Beijing, China

    1 shared publication
  • Wei Chen

    Department of Spine Surgery Beijing Jishuitan Hospital Peking University Fourth School of Clinical Medicine Beijing 100035 China

    1 shared publication
  • Wenzhe Huang

    Department of Spine Surgery Beijing Jishuitan Hospital Peking University Fourth School of Clinical Medicine Beijing 100035 China

    1 shared publication

Latest Publications

  • Macrophage‐Targeted Efferocytosis Therapy Promotes Diabetic Wound Healing via Cellular Level Debridement

    by Yi Chen, Wei Chen, Yiming Ren, Yanjie Zhang, Zhaoqi Tan, Wenzhe Huang, Xueshan Bai, Liya Yang, Shuyun Liu, Quanyi Guo, et al.

    Impaired efferocytosis in diabetic wounds contributes to apoptotic cell accumulation, chronic inflammation, and poor healing outcomes. In this study, a multi‐hierarchical hydrogel designed to facilitate cellular debridement and initiate a healing process in diabetic wounds is proposed. A reactive oxygen species (ROS)/glucose‐responsive hydrogel conjugated with chemokine aptamers is developed that encapsulated mannose‐modified lipid nanoparticles (mLNPs) loaded with ADAM17 siRNA (A disintegrin and metalloproteinase 17). This hydrogel enhanced macrophage recruitment by enriching endogenous chemokines. Additionally, it responded to the pathological microenvironment, enabling the dynamic release of mLNPs for targeted siRNA delivery to macrophages. Treatment with ADAM17 siR@mLNPs significantly enhanced macrophage efferocytosis through the MerTK‐Rac1 pathway and glycolytic reprogramming, thereby initiating the resolution of inflammation and tissue repair. Finally, in animal models of diabetic wounds, this therapy reduced the apoptotic burden and improved wound healing. In conclusion, macrophage‐targeted efferocytosis‐reactivation therapy is a promising strategy for the treatment of diabetic wounds.